{
    "response": "**Overall Treatment Decision:** Yes.\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute severe optic neuritis and myelitis Improves speed of neurological recovery Standard first-line therapy for inflammatory demyelinating relapse\n\n*   **Treatment:** Proton pump inhibitor during high-dose steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastric protection with corticosteroids Reduces risk of steroid-related dyspepsia/ulcer\n\n*   **Treatment:** Venous thromboembolism prophylaxis and early physiotherapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility from spastic paraparesis Prevents deconditioning and DVT\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Escalate if poor response to steroids within 48\u201372 hours Indicated early if AQP4-IgG positive or vision remains hand movements only\n\n*   **Treatment:** High-efficacy MS disease-modifying therapy (e.g., ocrelizumab) or NMOSD-directed therapy if indicated\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate after diagnostic confirmation and serology results Requires infection screening and vaccination review\n\n*   **Treatment:** Baclofen for spasticity as needed\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Introduce after acute phase if persistent spasticity limits function Dose titration guided by response and side effects\n\n*   **Treatment:** Urgent neurosurgical consultation for decompression if MRI shows cord compression\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Definitive treatment for compressive myelopathy Only indicated if imaging identifies a structural lesion\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute severe optic neuritis and myelitis\", \"Improves speed of neurological recovery\", \"Standard first-line therapy for inflammatory demyelinating relapse\"]}, {\"treatment\": \"Proton pump inhibitor during high-dose steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Gastric protection with corticosteroids\", \"Reduces risk of steroid-related dyspepsia/ulcer\"]}, {\"treatment\": \"Venous thromboembolism prophylaxis and early physiotherapy\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility from spastic paraparesis\", \"Prevents deconditioning and DVT\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges)\", \"timing\": \"Delay\", \"reasons\": [\"Escalate if poor response to steroids within 48\\u201372 hours\", \"Indicated early if AQP4-IgG positive or vision remains hand movements only\"]}, {\"treatment\": \"High-efficacy MS disease-modifying therapy (e.g., ocrelizumab) or NMOSD-directed therapy if indicated\", \"timing\": \"Delay\", \"reasons\": [\"Initiate after diagnostic confirmation and serology results\", \"Requires infection screening and vaccination review\"]}, {\"treatment\": \"Baclofen for spasticity as needed\", \"timing\": \"Delay\", \"reasons\": [\"Introduce after acute phase if persistent spasticity limits function\", \"Dose titration guided by response and side effects\"]}, {\"treatment\": \"Urgent neurosurgical consultation for decompression if MRI shows cord compression\", \"timing\": \"Delay\", \"reasons\": [\"Definitive treatment for compressive myelopathy\", \"Only indicated if imaging identifies a structural lesion\"]}]"
}